Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. (Nasdaq: ENTA) is a biotechnology company that discovers and develops small-molecule drugs for virology and immunology indications. Its wholly owned development programs include zelicapavir and EDP-323, oral antiviral candidates targeting different RSV proteins, and preclinical oral… From the company’s description.
Over the twelve months to Jun 30, 2026, Enanta Pharmaceuticals, Inc. reported revenue of $65.26M, up 0.7% from a year earlier, and a net loss of $63.23M. Its operating margin was −90.0%, and operations used $35.32M in cash. In fiscal 2025, it reported revenue of $65.32M, down 3.4% from fiscal 2024, and a net loss of $81.89M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Enanta Pharmaceuticals, Inc. does
In the company’s own words
Enanta Pharmaceuticals, Inc. (Nasdaq: ENTA) is a biotechnology company that discovers and develops small-molecule drugs for virology and immunology indications. Its wholly owned development programs include zelicapavir and EDP-323, oral antiviral candidates targeting different RSV proteins, and preclinical oral inhibitors targeting KIT and STAT6 for mast-cell-driven and type 2 inflammatory diseases. Its immunology research initially focuses on chronic spontaneous urticaria and atopic dermatitis, with potential applications in other inflammatory conditions. Enanta also earns royalties from AbbVie’s MAVYRET in the United States and MAVIRET internationally, fixed-dose HCV treatment combining Enanta-discovered glecaprevir with AbbVie’s pibrentasvir; the regimen has been marketed since 2017. Enanta previously developed two HCV protease inhibitors with AbbVie, and its first-generation inhibitor, paritaprevir, was used in earlier AbbVie regimens. The company reports $188.9 million in cash, cash equivalents and short-term marketable securities as of September 30, 2025.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WATERTOWN, MA
- Fiscal year end
- September
- CIK
- 1177648
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Enanta Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Enanta Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Enanta Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Enanta Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Enanta Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”